文献速递帕金森病与运动障碍认知障碍与痴呆

帕金森病患者粪便和血浆短链脂肪酸水平与肠道菌群及临床严重程度的关联

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
PubMed 文献 · Neurology · 2022-01-07

研究纳入96例帕金森病患者和85名健康对照,比较粪便与血浆短链脂肪酸水平及其与肠道菌群和临床严重程度的关系。结果显示患者粪便短链脂肪酸降低而血浆升高,且与运动及认知评分相关,产短链脂肪酸菌与粪便水平的关联在患者中消失。该研究提供III级证据表明短链脂肪酸可区分患者与对照并与疾病严重程度相关。

要点

  • 帕金森病患者粪便乙酸、丙酸、丁酸低于对照,血浆水平高于对照。
  • MDS-UPDRS第三部分运动评分与粪便乙酸、丙酸、丁酸降低及血浆丙酸升高相关。
  • MMSE评分与血浆丁酸和戊酸水平负相关。

核心结论

  • 帕金森病患者粪便短链脂肪酸降低而血浆短链脂肪酸升高,并与特定肠道菌群改变及疾病临床严重程度相关。

研究设计与样本

  • 队列研究,纳入台湾大学医院的96例帕金森病患者和85名对照,采用色谱和质谱测定粪便及血浆短链脂肪酸,宏基因组鸟枪法测序分析肠道菌群,并评估体重指数、合并症及饮食信息。

主要发现

  • 与对照相比,帕金森病患者粪便乙酸、丙酸和丁酸浓度较低而血浆浓度较高。
  • 调整年龄、性别、病程和抗帕金森病药物剂量后,帕金森病患者MDS-UPDRS第三部分运动评分与粪便乙酸降低(ρ=-0.37,p=0.012)、丙酸降低(ρ=-0.32,p=0.036)、丁酸降低(ρ=-0.40,p=0.004)及血浆丙酸升高(ρ=0.26,p=0.042)相关。
  • 调整混杂因素后,MMSE评分与血浆丁酸(ρ=-0.09,p=0.027)和戊酸(ρ=-0.032,p=0.033)水平负相关。
  • 产短链脂肪酸肠道菌与粪便短链脂肪酸水平在健康对照中正相关,但在帕金森病患者中无关联。
  • 帕金森病患者中促炎微生物如Clostridiales bacterium NK3B98和Ruminococcus sp AM07-15的丰度与粪便短链脂肪酸降低及血浆短链脂肪酸(尤其丙酸)升高显著相关。

关键数值与推荐

  • 该研究提供III级证据表明肠道代谢物短链脂肪酸可区分帕金森病患者与对照,并与患者疾病严重程度相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Short-chain fatty acids (SCFAs) are gut microbial metabolites that promote the disease process in a rodent model of Parkinson disease (PD), but fecal levels of SCFAs in patients with PD are reduced. Simultaneous assessments of fecal and plasma SCFA levels, and their interrelationships with the PD disease process, are scarce. We aimed to compare fecal and plasma levels of different SCFA subtypes in patients with PD and healthy controls to delineate their interrelations and link to gut microbiota changes and clinical severity of PD. METHODS: A cohort of 96 patients with PD and 85 controls were recruited from National Taiwan University Hospital. Fecal and plasma concentrations of SCFAs were measured using chromatography and mass spectrometry. Gut microbiota was analyzed using metagenomic shotgun sequencing. Body mass index and medical comorbidities were evaluated and dietary information was obtained using a food frequency questionnaire. To assess motor and cognitive impairment, we used the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the Mini-Mental Status Examination (MMSE). RESULTS: Compared with controls, patients with PD had lower fecal but higher plasma concentrations of acetate, propionate, and butyrate. After adjustment for age, sex, disease duration, and anti-PD medication dosage, MDS-UPDRS part III motor scores correlated with reduced fecal levels of acetate (ρ = -0.37, p = 0.012), propionate (ρ = -0.32, p = 0.036), and butyrate (ρ = -0.40, p = 0.004) and with increased plasma propionate concentrations (ρ = 0.26, p = 0.042) in patients with PD. MMSE scores negatively correlated with plasma levels of butyrate (ρ = -0.09, p = 0.027) and valerate (ρ = -0.032, p = 0.033) after adjustment for confounders. SCFAs-producing gut bacteria correlated positively with fecal levels of SCFAs in healthy controls but revealed no association in patients with PD. In the PD patient group, the abundance of proinflammatory microbes, such as Clostridiales bacterium NK3B98 and Ruminococcus sp AM07-15, significantly correlated with decreased fecal levels and increased plasma levels of SCFAs, especially propionic acid. DISCUSSION: Reductions in fecal SCFAs but increased plasma SCFAs were observed in patients with PD and corelated to specific gut microbiota changes and the clinical severity of PD. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that gut metabolite SCFAs distinguish between patients with PD and controls and are associated with disease severity in patients with PD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Chen SJ, Chen CC, Liao HY, et al. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease. Neurology. 2022. PMID: 34996879. doi:10.1212/WNL.0000000000013225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。